Chairman Mr. Osagie Imasogie and Global CEO Dr. Oludare Odumosu provide an update on 2025 milestones and the outlook for Zelira Therapeutics.
Chairman Mr. Osagie Imasogie and CEO Dr. Oludare Odumosu deliver commentary on key milestones achieved in FY24 and the priorities and outlook for the company.
Chairman Mr Osagie Imasogie and Global CEO Dr Oludare Odumosu provide investors with an update on the recent progress with the FDA pre-IND meeting and next steps for the HOPE SPV. The formal presentation is followed by a Q&A session.
Chairman Osagie Imasogie and CEO Dr Oludare Odumosu deliver the AGM presentation
Osagie Imasogie (Chairman) and Oludare Odumosu (Global CEO) take investors and analysts through the top line comparative trial results of Zelira’s diabetic nerve pain drug vs Lyrica® including efficacy, safety and next steps for the organisation.
Chairman Osagie Imasogie and CEO Oludare Odumosu lead a presentation on the creation of an SPV and US $8.6M cornerstone funding from Cantheon Capital LLC for HOPE 1 Ph.2 and Ph.3 US FDA clinical trials.
H&P’s updated report on Zelira highlighted by the completed enrolment of participants in the diabetic nerve pain trial